TIGIT predominantly regulates the immune response via regulatory T cells.

Autor: Kurtulus S, Sakuishi K, Ngiow SF, Joller N, Tan DJ, Teng MW, Smyth MJ, Kuchroo VK, Anderson AC

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2024 Jul 01; Vol. 134 (13). Date of Electronic Publication: 2024 Jul 01.

Systemic administration of IL-33 induces a population of circulating KLRG1 ^hi type 2 innate lymphoid cells and inhibits type 1 innate immunity against multiple myeloma.

Autor: Guillerey C; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.; School of Medicine, The University of Queensland, Herston, QLD, Australia., Stannard K; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia., Chen J; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.; School of Medicine, The University of Queensland, Herston, QLD, Australia., Krumeich S; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia., Miles K; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia., Nakamura K; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia., Smith J; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.; School of Environment and Sciences, Griffith University, Brisbane, QLD, Australia., Yu Y; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia., Ng S; Immunology and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia., Harjunpää H; School of Medicine, The University of Queensland, Herston, QLD, Australia.; Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia., Teng MW; Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia., Engwerda C; Immunology and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia., Belz GT; Immunology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, VIC, Australia., Smyth MJ; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.; School of Medicine, The University of Queensland, Herston, QLD, Australia.

Publikováno v: Immunology and cell biology [Immunol Cell Biol] 2021 Jan; Vol. 99 (1), pp. 65-83. Date of Electronic Publication: 2020 Sep 18.

Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.

Autor: Guillerey C; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.; School of Medicine, The University of Queensland, Herston, Queensland, Australia.; Cancer Immunotherapies Laboratory, Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia., Nakamura K; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Pichler AC; Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France., Barkauskas D; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Krumeich S; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Stannard K; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Miles K; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Harjunpää H; School of Medicine, The University of Queensland, Herston, Queensland, Australia.; Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Yu Y; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Casey M; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Doban AI; ASML Netherlands B.V., Veldhoven, Netherlands., Lazar M; Department of Electrical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands., Hartel G; Statistics Unit and., Smith D; Statistics Unit and., Vuckovic S; Bone Marrow Transplantation Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.; Multiple Myeloma Research Group, Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia., Teng MW; Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Bergsagel PL; Comprehensive Cancer Center, Mayo Clinic, Scottsdale, Arizona, USA., Chesi M; Comprehensive Cancer Center, Mayo Clinic, Scottsdale, Arizona, USA., Hill GR; Bone Marrow Transplantation Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Martinet L; Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France., Smyth MJ; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.; School of Medicine, The University of Queensland, Herston, Queensland, Australia.

Publikováno v: JCI insight [JCI Insight] 2019 Jun 13; Vol. 5. Date of Electronic Publication: 2019 Jun 13.

IL-23 promotes the development of castration-resistant prostate cancer.

Autor: Yan J; Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.; School of Medicine, University of Queensland, Brisbane, Australia., Cua DJ; Merck Research Laboratories, Palo Alto, CA, USA., Teng MW; Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.; School of Medicine, University of Queensland, Brisbane, Australia.

Publikováno v: Immunology and cell biology [Immunol Cell Biol] 2018 Oct; Vol. 96 (9), pp. 883-885. Date of Electronic Publication: 2018 Sep 08.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.

Autor: Slaney CY; Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia. michael.kershaw@petermac.org clare.slaney@petermac.org.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., von Scheidt B; Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Davenport AJ; Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Beavis PA; Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Westwood JA; Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Mardiana S; Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Tscharke DC; John Curtin School of Medical Research, Australian National University, Canberra, Australia., Ellis S; Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Prince HM; Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Trapani JA; Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Johnstone RW; Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Smyth MJ; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Teng MW; Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Ali A; Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Yu Z; Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, Maryland., Rosenberg SA; Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, Maryland., Restifo NP; Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, Maryland., Neeson P; Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Darcy PK; Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.; Department of Immunology, Monash University, Clayton, Australia., Kershaw MH; Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia. michael.kershaw@petermac.org clare.slaney@petermac.org.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.; Department of Immunology, Monash University, Clayton, Australia.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 May 15; Vol. 23 (10), pp. 2478-2490. Date of Electronic Publication: 2016 Dec 13.